IROC®
IMAGING AND
RADIATION ONCOLOGY CORE
Global Leaders in Clinical Trial Quality Assurance

NCI National Clinical Trials Network
a National Cancer Institute program

ANNOUNCEMENT · NCI ETCTN, NCTN & NCORP SITES

Lu-177 Dosimetry site qualification

Up to 40
U.S. sites

No charge
phantom-based qualification

February 2027
expected completion

Successful completion leads to IROC site qualification and can also be used for SNMMI TCTN eligibility.

THE OPPORTUNITY

IROC, the Imaging and Radiation Oncology Core of the NCI NCTN (U24CA180803), announces a unique opportunity enabled by a supplement initiated by the NCI Cancer Imaging Program for up to 40 sites to be qualified using a NIST-referenced Lu-177 source and the processes established in the FNIH Precision Dosimetry Imaging Biomarker (PDIB) project, in collaboration with the Society of Nuclear Medicine and Molecular Imaging.

SITE REQUIREMENTS

Sites must have access to recent-generation SPECT/CT systems suitable for quantitative Lu-177 applications.

WHO CAN APPLY

U.S.-based sites that actively participate in the NCI ETCTN, NCTN or NCORP programs, including sites affiliated with the NCTN network groups: Alliance, COG, ECOG-ACRIN, NRG and SWOG. Limited to the U.S. due to shipping restrictions.

HOW SITES ARE SELECTED

The IROC Executive Committee in consultation with the NCTN Theranostics Committee, NCI CIP, and SNMMI will select up to 40 sites based on technical, enrollment and site characteristics on a first-come basis.

HOW TO APPLY

Scan to complete a brief questionnaire

QUESTIONS

Contact your IROC QA Center or
help@IROCOhio.org

CANCER IMAGING PROGRAM (CIP)

Lalitha Shankar, MD, PhD
Acting Associate Director

NIH NATIONAL CANCER INSTITUTE
Division of Cancer Treatment & Diagnosis

SNMMI SOCIETY OF NUCLEAR MEDICINE & MOLECULAR IMAGING

FNIH Foundation for the National Institutes of Health

FNIH PDIB public sector partners: ANSTO · SCK CEN · NCI · NPL · NIST · CNRC · FDA